<DOC>
	<DOCNO>NCT00136396</DOCNO>
	<brief_summary>The purpose study determine rituximab safe effective therapy steroid-refractory chronic graft versus host disease ( GVHD ) .</brief_summary>
	<brief_title>Rituximab Therapy Steroid-Refractory Chronic Graft Versus Host Disease</brief_title>
	<detailed_description>Patients receive rituximab intravenously one time per week four consecutive week . Once therapy complete , patient weekly visit physician four week , complete simple questionnaire design evaluate severity chronic graft versus host disease . At end eighth week study ( 4 week study treatment 4 week observation ) , patient evaluate determine whether chronic graft versus host disease ( GVHD ) resolve . If chronic graft versus host disease resolve entirely , patient monitor remainder year . If initial eight week study patient still symptoms sign GVHD , may receive second four week study treatment . If patient ' chronic GVHD reappear receive either one two course rituximab , third final four week course medication give provide least eight week since last dose . Blood test perform begin study , 8 week study , 16 week study end 1 year .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Recipients match related , match unrelated , mismatched stem cell transplantation At least 180 day since allogeneic stem cell transplantation procedure Patients must steroidrefractory chronic GVHD , define persistent sign symptom despite use prednisone Stable dose corticosteroid 4 week prior enrollment Adequate bone marrow function : absolute neutrophil count ( ANC ) &gt; 500/mm ; platelet &gt; 20,000 ul Adequate renal function : creatinine &lt; 3.0 mg/dl Adequate hepatic function : bilirubin &lt; 3.0 mg/dl ; AST &lt; 90 IU Prednisone requirement great 2 mg/kg/day equivalent Known lifethreatening sensitivity rituximab antiB cell antibody . Prior exposure new immunosuppressive medication precede 4 week prior enrollment . Active , uncontrolled infection Evidence natural exposure hepatitis B C. Active malignant disease relapse Donor lymphocyte infusion within precede 100 day . Life expectancy le 3 month . Pregnancy lactation Evidence HIV seropositivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Steroid-refractory Chronic Graft v . Host Disease</keyword>
	<keyword>Chronic Graft v . Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>steroid-refractory</keyword>
	<keyword>rituximab</keyword>
</DOC>